PEAR News and Press, Pear Therapeutics Inc. From 12/15/22

Alcohol is the most common substance use disorder (SUD), representing 70% of the more than 40 million people with SUD 1 New data from real-world use of reSET® demonstrate patients who use alcohol exhibit robust engagement, retention, and abstinence Pear Ther...

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30,...

Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Director-Corporate Communications Corey McCann – President and Chief Executive Officer Ronan O'Brien – Gene...

Pear Therapeutics press release ( NASDAQ: PEAR ): Q3 GAAP EPS of -$0.22 in-line. Revenue of $4.1M misses by $0.24M . "We continue to break down the barriers to patient access for PDTs, evidenced by our increasing payment rate and new coverage decisions. In addition...

Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter operating expenses and cut expected 2023 operating ...

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management’s participation in the virtual BTIG Digital Health Forum being held on Monday, November 21...

Somryst® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia Analysis demonstrated potential per-patient cost reductions over 24 months of $8,202 compared to use of insomnia medications alone Pear Therape...

The Wisconsin Department of Health Services awards Pear funding towards access to Pear’s reSET ® and reSET-O ® to patients with substance use disorder and opioid use disorder The program will support Wisconsinites on their recovery journeys with ...

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Credit Suisse 31 st Annual Healthcare Conference in Rancho Palos Ver...

Pear Therapeutics, Inc. (the “Company”) (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of mark...